Uranium equities were sold off recently following the news that production by Kazatomprom would remain unchanged. It appears the market had speculated there would be production cuts related to tight availability of sulphuric acid. PDN has retracted to within range of our Price Target, prompting a recommendation update from Sell to Hold. Execution of the Fission Uranium acquisition remains ongoing. We view this deal as value accretive and failure to complete would negatively impact our Price Target. Finalisation of the deal could also make PDN itself an attractive target for a larger acquirer.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.
